Intravenous Metoprolol for Acute Rate Control in Atrial Fibrillation

Dosing Protocol

• Administer 5 mg of IV metoprolol over 1–2 minutes as the initial bolus, then repeat a 5 mg bolus every 5 minutes as needed, up to a maximum cumulative dose of 15 mg for hemodynamically stable adults with atrial fibrillation and rapid ventricular response. 1
• After each bolus, wait 5 minutes and reassess heart rate and blood pressure before giving the next dose. 1
• If the heart rate remains >100 bpm or has decreased <20 % from baseline, a second 5 mg bolus may be given; a third bolus can be considered after another 5 minutes if further control is required. 1
• The pharmacologic effect of each bolus is typically evident within 5 minutes. 1
• Prior to each additional dose, verify that systolic blood pressure is ≥90 mmHg and that heart rate is ≥60 bpm; hypotension (SBP < 90 mmHg) or excessive bradycardia (HR < 60 bpm) should prompt dose omission. 1

Patient Selection

• Suitable candidates are hemodynamically stable patients with systolic blood pressure ≥90 mmHg who present with atrial fibrillation and a ventricular rate >100 bpm requiring acute rate control. 2
• Patients must not have second‑ or third‑degree atrioventricular block or sick‑sinus syndrome. 1

Contraindications

• Absolute contraindications – severe bronchospasm, asthma, or other obstructive airway disease (risk of precipitating bronchospasm). 1
• Acute decompensated heart failure with signs of volume overload or cardiogenic shock (risk of worsening heart failure). 1
• Pre‑excited atrial fibrillation (e.g., Wolff‑Parkinson‑White syndrome) because AV‑node blockade can accelerate ventricular response via accessory pathways. 1
• High‑degree AV block (second‑ or third‑degree) in patients without a permanent pacemaker. 1

Comparative Effectiveness

• Both metoprolol and diltiazem are Class I first‑line agents for acute rate control in atrial fibrillation with rapid ventricular response. 2
• In patients with acute decompensated heart failure and volume overload, both agents should be avoided; digoxin (0.25 mg IV every 2 hours up to 1.5 mg) or amiodarone (150 mg IV over 10 minutes) are preferred alternatives. 2

Safety Considerations

• Hypotension – the most common adverse effect, occurring especially in patients with baseline systolic BP 90–110 mmHg or when cumulative doses approach 15 mg. If SBP falls below 90 mmHg, discontinue further metoprolol and consider IV fluids or vasopressor support. 1
• Bradycardia and AV block – monitor for HR < 60 bpm or development of second‑ or third‑degree block, particularly in those with pre‑existing conduction abnormalities. If symptomatic bradycardia or high‑grade block occurs, stop metoprolol and treat with atropine 0.5–1 mg IV or temporary pacing. 1
• Dose ceiling – exceeding the 15 mg total IV dose provides no additional rate‑control benefit and markedly increases the risk of hypotension and bradycardia. 1

Alternative Short‑Acting β‑Blockers

• Dosing and safety data for esmolol and propranolol are derived from guideline recommendations (Circulation 2010). 1

Inpatient Management of Rate‑Controlled Atrial Fibrillation: Continue Metoprolol

Guideline‑Based Recommendations

• The American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) give a Class I recommendation that heart‑rate measurement and control with beta‑blockers or nondihydropyridine calcium‑channel antagonists be performed in all patients with persistent or permanent atrial fibrillation.  [3][4]5
• ACC/AHA/ESC guidelines state that rate‑control combined with chronic anticoagulation is the preferred strategy for the majority of atrial‑fibrillation patients because rhythm‑control has not demonstrated superiority in reducing morbidity or mortality. [6][7]
• The European Heart Journal (2024) recommends metoprolol, diltiazem, or verapamil as first‑line agents for rate control both at rest and during exercise in patients with atrial fibrillation and left‑ventricular ejection fraction > 40 %. 8

Acute Rate‑Control in the Hospital

• For hemodynamically stable patients with rapid ventricular response, intravenous metoprolol 5 mg bolus every 5 minutes (up to a total of 15 mg) is recommended to achieve rapid rate control. [9][10]

Transition to Oral Maintenance Therapy

• After successful IV rate control, the therapeutic goal shifts to ongoing oral rate‑control; discontinuation of metoprolol is not advised simply because the heart rate is presently controlled. [3][4]
• Recommended oral maintenance dosing: metoprolol tartrate 25–200 mg twice daily or metoprolol succinate 50–400 mg once daily. 11
• Heart‑rate adequacy should be re‑evaluated during exercise, and medication doses adjusted to keep the ventricular rate within the physiological range; this necessitates continued therapy. [3][4]12

Ongoing Inpatient Management

• Continue metoprolol at the dose that achieved rate control, converting from IV to the appropriate oral formulation. 11
• Monitor heart rate and blood pressure; if bradycardia or hypotension develops, reduce the dose or switch agents rather than stopping abruptly. [9][10]
• Evaluate for contraindications to beta‑blockers (e.g., severe bronchospasm, decompensated heart failure, high‑grade AV block without a pacemaker) and consider alternative rate‑control drugs when present. [9][10]

Anticoagulation Considerations

• Rate control does not eliminate thromboembolic risk; all patients with atrial fibrillation should receive chronic anticoagulation based on their CHA₂DS₂‑VASc score, independent of rate‑control status. [3][4]12

Situations Where Rate‑Control May Be Modified

• Patients who successfully cardiovert to sinus rhythm and remain in sinus rhythm may discontinue chronic rate‑control therapy, but this decision must be made after careful assessment—not merely because the ventricular rate is controlled while in atrial fibrillation. [6][7]

Common Pitfalls to Avoid

• Mistaking a controlled ventricular rate for conversion to sinus rhythm leads to inappropriate discontinuation of rate‑control medication. [3][4]
• Assuming that inpatient rate control is only an acute measure overlooks its role as a chronic management strategy. [6][7]

All statements are supported by the cited references and reflect the strength of evidence indicated in the respective guideline documents.